| Dr Tho Dinh Le, MD | |
|
6151 S Yale Ave, #a100, Tulsa, OK 74136-1907 | |
| (918) 494-8500 | |
| (918) 307-5578 |
| Full Name | Dr Tho Dinh Le |
|---|---|
| Gender | Male |
| Speciality | Cardiovascular Disease (cardiology) |
| Experience | 36 Years |
| Location | 6151 S Yale Ave, Tulsa, Oklahoma |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1134193832 | NPI | - | NPPES |
| 200115790A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 25766 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Saint Francis Hospital South, Llc | Tulsa, OK | Hospital |
| Saint Francis Hospital, Inc | Tulsa, OK | Hospital |
| Saint Francis Hospital Muskogee | Muskogee, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Saint Francis Hospital South Llc | 7113829847 | 22 |
| Warren Clinic Inc | 8820900293 | 604 |
| Saint Francis Hospital, Inc. | 9537061171 | 40 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Entity Name | Warren Clinic Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1174582282 PECOS PAC ID: 8820900293 Enrollment ID: O20031104000252 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Entity Name | Laureate Psychiatric Clinic And Hospital Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1710985064 PECOS PAC ID: 3971599218 Enrollment ID: O20040422000800 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Entity Name | Saint Francis Hospital, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144228487 PECOS PAC ID: 9537061171 Enrollment ID: O20070330000494 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Entity Name | Saint Francis Hospital South Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376561944 PECOS PAC ID: 7113829847 Enrollment ID: O20080624000603 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Entity Name | Saint Francis Hospital Vinita, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1700334232 PECOS PAC ID: 7911289780 Enrollment ID: O20180308001897 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Entity Name | Saint Francis Hospital Muskogee Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1386188837 PECOS PAC ID: 7315216215 Enrollment ID: O20180731002274 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Tho Dinh Le, MD 6600 S Yale Ave, Ste 1200, Tulsa, OK 74136-3361 Ph: (918) 488-6687 | Dr Tho Dinh Le, MD 6151 S Yale Ave, #a100, Tulsa, OK 74136-1907 Ph: (918) 494-8500 |
News Archive
454 Life Sciences Corporation, in collaboration with scientists at the Human Genome Sequencing Center, Baylor College of Medicine, announced in Houston, Texas, the completion of a project to sequence the genome of James D. Watson, Ph.D., co-discoverer of the double-helix structure of DNA.
After unanimously voting to recommend a miraculous hepatitis C drug for approval in 2013, a panel of experts advising the Food and Drug Administration gushed about what they'd accomplished.
Cadence Pharmaceuticals, Inc. today announced that its underwriters partially exercised their over-allotment option in connection with its previously announced public offering that priced on November 11, 2010, by purchasing an additional 1,000,000 shares of its common stock at a public offering price of $8.00 per share. Including the over-allotment shares purchased, Cadence sold a total of 12,500,000 shares in the offering, resulting in expected aggregate gross proceeds to the company of $100 million.
Secondary analyses of findings from the Women's Health Initiative (WHI) suggest that women who begin hormone therapy within 10 years of menopause may have less risk of coronary heart disease (CHD) due to hormone therapy than women farther from menopause.
› Verified 7 days ago
Sarah Anne Shaw-dressler, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave Ste 100a, Tulsa, OK 74136 Phone: 918-494-8500 Fax: 918-307-5578 | |
Julia Margaret Kwon, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 1705 E 19th St Ste 302, Tulsa, OK 74104 Phone: 918-748-7585 Fax: 918-748-7539 | |
Peter Madden, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 E 41st St, Tulsa, OK 74135 Phone: 918-619-4400 | |
Thao Tran, D.O Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 4502 E. 41st Street, Tulsa, OK 74135 Phone: 918-619-4400 | |
Robert Peter Aran, D.O. Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 6160 S Yale Ave Ste 100, Tulsa, OK 74136 Phone: 918-497-3300 Fax: 918-497-3365 | |
Robert Dean Okada, MD Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 6151 S Yale Ave, Ste 304, Tulsa, OK 74136 Phone: 918-494-5300 Fax: 918-494-5455 | |
Dr. Charles Wade Taylor, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 12697 E 51st St, Tulsa, OK 74146 Phone: 918-505-3200 Fax: 918-505-3253 |